|
|
To: Superintendents, School Nurses, Communicable Disease Preparedness Liaisons, Principals, Charter School Leaders, K-12 Public Information
From: Kati Moseley, Administrator, Health in Education; Ely Sanders, Education Specialist, School Health Services
Date: August 29, 2024
Re: Communicable disease guidance update and required information to be shared with parents and guardians about Opioid Antagonists (Naloxone)
Welcome back to another school year! Thank you for your dedication to the health and well-being of Oregon’s students. As we navigate the new school year, we want to share important health related updates:
In This Message
-
Updated Communicable Disease Guidance from Oregon Department of Education (ODE) and the Oregon Health Authority (OHA). OHA in partnership with ODE has updated the School Communicable disease guidance for the 2024-25 school year. Key updates include:
- Recommendation that students who have experienced diarrhea or vomiting to return to school once they are symptom-free for 24 hours OR with orders from doctor to school nurse. Past guidance had recommended symptom-free for 48 hours before students returned to school.
- You can find the updated communicable disease guidance and resources including a parent letter here.
-
Letter/email template to communicate to parents and guardians, information related to opioid antagonists (naloxone).
- PER ORS 339.869 and OAR 581-021-0037 all school districts must provide information related to opioid antagonists (naloxone) to the parent or guardian of each minor student. The information provided must at a minimum include:
- A description of short-acting opioid antagonists and their purpose;
- A statement regarding, in an emergency situation, the risks of administering to an individual a short-acting opioid antagonist and the risks of not administering to an individual a short-acting opioid antagonist;
- A statement identifying which schools in the district, if any, will have short-acting opioid antagonists, and the necessary medical supplies to administer short-acting opioid antagonists, on site and available for emergency situations; and
- A statement that a representative of a district may administer to a student a short-acting opioid antagonist in an emergency if the student appears to be unconscious and experiencing an opioid overdose.
- ODE has developed a letter that districts may use to communicate to parents and guardians that meets the above requirements. Thank you for your help to build awareness about the dangers of opioid use and the availability of naloxone in schools.
Contact Us
|
|
|
|
